Rajasekaran A, Kalaivani M
KMCH College of Pharmacy, Coimbatore, India.
Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Govt. of India, Sector-23, Raj Nagar, Ghaziabad, 201 002 India.
J Food Sci Technol. 2015 Mar;52(3):1434-43. doi: 10.1007/s13197-013-1191-8. Epub 2013 Oct 11.
In the present study, anti-diabetic activity and nephroprotective effect of MMFR was evaluated by using STZ-induced diabetic rats. Administration of MMFR at 100 and 200 mg/kg bw showed significant (P < 0.01) anti-hyperglycemic activity by lowering blood glucose level, HbA1C and increasing body weight. Altered lipid profiles in diabetic rats were restored to normal level on treatment with MMFR and showed significant (P < 0.01) decrease in the elevated levels of biochemical parameters. MMFR produced significant (P < 0.01) improvement in antioxidant levels in kidney. Food safety of MFR produced by using mutant Monascus purpureus 254 (MMFR) was evaluated for genotoxicity and oral acute toxicity. In Ames mutagenicity assay MMFR doesn't showed any toxicity to the test strain S. typhimurium till 5 mg/plate. Acute toxicity study also recorded no toxicity till the dose of 5,000 mg/kg bw. The study concluded that MMFR, not only possess anti-diabetic activity but also prevents nephropathy and hypercholesterolemia due to diabetes.
在本研究中，通过使用链脲佐菌素诱导的糖尿病大鼠评估了突变型紫红红曲菌254（MMFR）的抗糖尿病活性和肾保护作用。以100和200mg/kg体重给予MMFR可通过降低血糖水平、糖化血红蛋白A1C并增加体重显示出显著（P＜0.01）的抗高血糖活性。糖尿病大鼠中改变的脂质谱在用MMFR治疗后恢复到正常水平，并且升高的生化参数水平显示出显著（P＜0.01）下降。MMFR使肾脏中的抗氧化剂水平产生了显著（P＜0.01）改善。对使用突变型紫红红曲菌254（MMFR）产生的MFR的食品安全进行了遗传毒性和口服急性毒性评估。在艾姆斯致突变性试验中，直到5mg/平板，MMFR对测试菌株鼠伤寒沙门氏菌均未显示任何毒性。急性毒性研究也记录到直到5000mg/kg体重的剂量都没有毒性。该研究得出结论，MMFR不仅具有抗糖尿病活性，还可预防糖尿病引起的肾病和高胆固醇血症。
